- Previous Close
0.0002 - Open
0.0002 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0002 - 52 Week Range
0.0001 - 2.0000 - Volume
5,737,000 - Avg. Volume
0 - Market Cap (intraday)
2,642 - Beta (5Y Monthly) -313.29
- PE Ratio (TTM)
-- - EPS (TTM)
-200.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
pharnext.comRecent News: ALPHA.PA
View MorePerformance Overview: ALPHA.PA
Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALPHA.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALPHA.PA
View MoreValuation Measures
Market Cap
2.64k
Enterprise Value
26.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
--
Enterprise Value/Revenue
2.62k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-277.44%
Return on Equity (ttm)
--
Revenue (ttm)
171.94k
Net Income Avi to Common (ttm)
-27.52M
Diluted EPS (ttm)
-200.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
13.22k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--